[ICAM-1 and allergic inflammation].
Recent progress in the understanding of the physiopathology of asthma makes possible the revision of the objectives of treatment, to pass from short-term symptomatic control to a prolonged control of the illness. L'ICAM-1 is an excellent potential target for preventative treatment of asthma of viral origin. When there are agents available of both inhibiting histamine and positively regulating ICAM-1 there is no longer reason to use simple antihistamines.
Canonica
G W
GW
Département de Médecine Interne, Université de Gênes, Italie.
D000485:Allergens / Q000276:immunology; D001249:Asthma / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D001991:Bronchitis / Q000150:complications* / Q000276:immunology / Q000473:pathology / Q000821:virology; D002448:Cell Adhesion; D004730:Endothelium, Vascular / Q000473:pathology*; D004848:Epithelium / Q000378:metabolism / Q000473:pathology; D005786:Gene Expression Regulation / Q000187:drug effects; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D007962:Leukocytes / Q000473:pathology*; D010850:Picornaviridae Infections / Q000150:complications*; D011991:Receptors, Virus / Q000502:physiology*; D012229:Rhinovirus / Q000502:physiology*
D000485:Allergens; D006634:Histamine H1 Antagonists; D011991:Receptors, Virus; D018799:Intercellular Adhesion Molecule-1